Is Alembic Pharmaceuticals Overvalued or Undervalued Right Now?

Is Alembic Pharmaceuticals overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 819.00, the stock trades roughly 17.9% below its 52 week high of Rs 998.00 and about 28.8% above its 52 week low of Rs 635.80.

Alembic Pharmaceuticals's share price moved up 0.68% in Monday's session to Rs 819.00, against a market capitalisation of Rs 16,000 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple.

Click Here – Get Free Investment Predictions

Alembic Pharmaceuticals Valuation Metrics: Where Does the Stock Stand?

Valuation Metric	Alembic Pharmaceuticals
CMP (31 Aug 2026)	Rs 819.00
Market Cap	Rs 16,000 Cr
P/E Ratio	23.20
Industry P/E	38.07
P/B Ratio	2.82
Sector Average P/B (pharmaceutical)	7.31
Return on Equity (ROE)	11.89%
Sector Average ROE (pharmaceutical)	12.94%
EPS (TTM)	Rs 35.08
Book Value per Share	Rs 288.70
Debt to Equity	0.25
Dividend Yield	1.47%
Sector Average Dividend Yield (pharmaceutical)	0.30%
52 Week High / Low	Rs 998.00 / Rs 635.80

The headline number here is the price to earnings ratio. At 23.20, the Alembic Pharmaceuticals PE ratio is 0.61 times the industry average of 38.07. Measured against its pharmaceutical sector peers, the gap widens further on other measures too: a P/B of 2.82 against a sector average of 7.31, and an ROE of 11.89% against a sector average of 12.94%.

Is Alembic Pharmaceuticals Overvalued Based on Its P/E Ratio?

Based on the P/E ratio alone, Alembic Pharmaceuticals looks undervalued. The stock's PE of 23.20 sits well below the industry average of 38.07, which can reflect either a genuine bargain or a market discounting some risk in the business that is not obvious from the ratio itself. Investors relying only on the PE ratio would classify Alembic Pharmaceuticals as cheaper than its peers, but the Alembic Pharmaceuticals PE ratio still needs to be read alongside its return ratios and earnings quality before concluding the stock is a genuine value opportunity.

Check Alembic Pharmaceuticals's Live Fundamentals on the Univest Screener

Alembic Pharmaceuticals's Financial Growth and Profitability

Alembic Pharmaceuticals's revenue moved from Rs 6,714.63 crore in FY2025 to Rs 7,399.31 crore in FY2026, a change of 10.2%. Net profit grew from Rs 582.01 crore to Rs 670.83 crore over the same period, a swing of roughly 15.3%.

The Alembic Pharmaceuticals share price has moved alongside this earnings trend, which is part of why the stock now trades at 0.61 times the industry PE of 38.07 rather than a flat multiple.

Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals's live share price and valuation ratios.

Arguments That Alembic Pharmaceuticals Could Be Overvalued

• Sector-wide re-rating risk: If sentiment toward the sector turns, a PE of 23.20 still has room to compress toward the industry average of 38.07.
• Limited margin of safety: At Rs 819.00, the stock is only 17.9% below its 52 week high of Rs 998.00, leaving less room for error if earnings disappoint.

Arguments Against a Discount

• Low leverage: A debt to equity ratio of 0.25 gives Alembic Pharmaceuticals a comparatively strong balance sheet.
• Reasonable income: A dividend yield of 1.47% offers some cushion while the market decides on the growth story.
• 52 week range context: At Rs 819.00, the stock is 28.8% above its 52 week low of Rs 635.80, showing it has already found some support at lower levels.

Verdict: Is Alembic Pharmaceuticals Overvalued or Undervalued Right Now?

On balance, Alembic Pharmaceuticals looks undervalued by traditional multiples, trading at a PE of 23.20 against an industry average of 38.07. That gap can close either through the share price catching up or through the business underperforming enough to justify the discount, so the read depends on which explanation fits the company's recent earnings trend better. A 11.89% ROE is a reasonable starting point for that judgement, but investors should weigh why the market has kept the stock at a discount before treating the gap as a straightforward opportunity.

What Could Change This Valuation Picture for Alembic Pharmaceuticals?

Two broad scenarios could shift this valuation call on Alembic Pharmaceuticals in either direction. On the upside, the market recognising the gap between the PE of 23.20 and the industry average of 38.07, which would show up as the share price re-rating higher without a change in earnings. On the downside, a genuine deterioration in the business that justifies the current discount, in which case the low PE would turn out to be a fair reflection of risk rather than a bargain. Investors watching the Alembic Pharmaceuticals share price over the next few quarters should track whether reported ROE holds near 11.89% and whether the PE gap versus the industry average of 38.07 widens or narrows, since both will matter more to the eventual answer than the current price point on its own.

Conclusion

Alembic Pharmaceuticals's numbers point to a stock that is undervalued on headline multiples, though its return ratios help explain part of the gap. Investors tracking the Alembic Pharmaceuticals share price should watch whether earnings growth can keep pace with the current PE of 23.20, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. This article is for informational purposes only and is not investment advice.

FAQs on Alembic Pharmaceuticals Valuation

Is Alembic Pharmaceuticals overvalued or undervalued right now?

Ans. Based on a PE ratio of 23.20 against an industry average of 38.07, Alembic Pharmaceuticals currently looks undervalued on relative valuation. Its 11.89% ROE is an important part of the picture alongside the PE ratio.

What is Alembic Pharmaceuticals's current PE ratio?

Ans. Alembic Pharmaceuticals's price to earnings ratio stands at 23.20, compared with an industry average PE of 38.07.

What is Alembic Pharmaceuticals's return on equity?

Ans. Alembic Pharmaceuticals generates a return on equity of 11.89%, against a sector average of 12.94% among pharmaceutical peers.

What is Alembic Pharmaceuticals's 52 week high and low?

Ans. Alembic Pharmaceuticals's 52 week high is Rs 998.00 and its 52 week low is Rs 635.80. The stock currently trades around Rs 819.00, roughly 17.9% below its high.

Does Alembic Pharmaceuticals have high debt?

Ans. Alembic Pharmaceuticals carries a debt to equity ratio of 0.25, which is low for its sector.

What is Alembic Pharmaceuticals's dividend yield?

Ans. Alembic Pharmaceuticals offers a dividend yield of 1.47% at the current share price.

Is Alembic Pharmaceuticals a good stock to buy at current levels?

Ans. Alembic Pharmaceuticals's current valuation suits investors who agree with the undervalued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.

What is Alembic Pharmaceuticals's price to book ratio?

Ans. Alembic Pharmaceuticals trades at a price to book ratio of 2.82, compared with a sector average of 7.31 among pharmaceutical peers.